The small molecule inhibitor SU056-mediated targeting of YB1 inhibits the Rb pathway in triple negative breast cancer tumors
Background Triple-negative breast cancer (TNBC) tumors lack expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, limiting the availability of targeted therapeutic options. As a result, TNBC is characterized by a high propensity for metastasis, rapid recurrence, and poor overall prognosis. Despite...